Pozniak A - Search Results

1

The effect of initiation of antiretroviral therapy on monocyte, endothelial and platelet function in HIV-1 infection.

O'Halloran JA, Dunne E, Gurwith M, Lambert JS, Sheehan GJ, Feeney ER, Pozniak A, Reiss P, Kenny D, Mallon P. O'Halloran JA, et al. Among authors: pozniak a. HIV Med. 2015 Nov;16(10):608-19. doi: 10.1111/hiv.12270. Epub 2015 Jun 25. HIV Med. 2015. PMID: 26111187 Free article.

2

Why switch from protease inhibitors (PI) to non-nucleoside reverse transcriptase inhibitors (NNRTI)?

Pozniak AL. Pozniak AL. HIV Med. 2000;1 Suppl 1:7-10. doi: 10.1046/j.1468-1293.2000.00006.x. HIV Med. 2000. PMID: 11737361 Free article. Review. No abstract available.

3

Continuing HIV therapy in the ICU.

Soni N, Pozniak A. Soni N, et al. Among authors: pozniak a. Crit Care. 2001 Oct;5(5):247-8. doi: 10.1186/cc1040. Epub 2001 Sep 13. Crit Care. 2001. PMID: 11737898 Free PMC article.

4

Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy.

Dean GL, Edwards SG, Ives NJ, Matthews G, Fox EF, Navaratne L, Fisher M, Taylor GP, Miller R, Taylor CB, de Ruiter A, Pozniak AL. Dean GL, et al. Among authors: pozniak al. AIDS. 2002 Jan 4;16(1):75-83. doi: 10.1097/00002030-200201040-00010. AIDS. 2002. PMID: 11741165

5

Mycobacterial diseases and HIV.

Pozniak A. Pozniak A. J HIV Ther. 2002 Feb;7(1):13-6. J HIV Ther. 2002. PMID: 11956499 Review.

6

Naively changing HAART.

Mandalia S, Parmar D, Fisher M, Pozniak A, Tang A, Youle M, Gazzard B, Beck EJ; NPMS-HHC Steering Group. Mandalia S, et al. Among authors: pozniak a. HIV Med. 2002 Oct;3(4):254-62. doi: 10.1046/j.1468-1293.2002.00110.x. HIV Med. 2002. PMID: 12444943 Free article.

7

British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy.

Pozniak A, Gazzard B, Anderson J, Babiker A, Churchill D, Collins S, Fisher M, Johnson M, Khoo S, Leen C, Loveday C, Moyle G, Nelson M, Peter B, Phillips A, Pillay D, Wilkins E, Williams I, Youle M; BHIVA Writing Committee BHIVA Executive Committee. Pozniak A, et al. HIV Med. 2003 Oct;4 Suppl 1:1-41. HIV Med. 2003. PMID: 14511246 Free article. No abstract available.

8

The prevalence of reduced zidovudine susceptibility in zidovudine-naive, antiretroviral-experienced HIV-1-infected patients.

Gilleece Y, Torti C, Mandalia S, Gazzard BG, Pillay D, Pozniak AL. Gilleece Y, et al. Among authors: pozniak al. HIV Med. 2003 Oct;4(4):305-10. doi: 10.1046/j.1468-1293.2003.00163.x. HIV Med. 2003. PMID: 14525540 Free article.

9

The influence of the M184V mutation in HIV-1 reverse transcriptase on the virological outcome of highly active antiretroviral therapy regimens with or without didanosine.

Sproat M, Pozniak AL, Peeters M, Winters B, Hoetelmans R, Graham NM, Gazzard BG. Sproat M, et al. Antivir Ther. 2005;10(2):357-61. Antivir Ther. 2005. PMID: 15865231

10

Clinical characteristics of IRIS syndrome in patients with HIV and tuberculosis.

Michailidis C, Pozniak AL, Mandalia S, Basnayake S, Nelson MR, Gazzard BG. Michailidis C, et al. Antivir Ther. 2005;10(3):417-22. doi: 10.1177/135965350501000303. Antivir Ther. 2005. PMID: 15918332

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

557 results

Search Page

Filters